TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1545087

Group type: EXPERIMENTAL
Intervention: Standardized allergen extracts (100,000, 10,000, and 1000 AU/ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional nonstandardized extracts (1:10 or 1:20 wt/vol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized and conventional extracts
Number of subjects: 0
Study: 6432415

Group type: EXPERIMENTAL
Intervention: Auranofin 3 mg b.d.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hydroxychloroquine 200 mg b.d.
Number of subjects: 40
Study: 30871608

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (hemoglobin threshold of 9 g/dL)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (hemoglobin threshold of 7 g/dL)
Number of subjects: 44
Study: 30135171

Group type: EXPERIMENTAL
Intervention: Intervention (navigators)
Number of subjects: 1877

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 1877
Study: 26762365

Group type: EXPERIMENTAL
Intervention: In-hospital exercise training programme (aerobic interval training for 6 to 9 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual care control group (usual care and no formal exercise training)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: In-hospital exercise training programme
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 46
Study: 24794760

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and fentanyl (D/F)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam and fentanyl (M/F)
Number of subjects: 60
Study: 22245607

Group type: EXPERIMENTAL
Intervention: LBVH0101
Number of subjects: 185

Group type: COMPARATOR
Intervention: Hiberix™
Number of subjects: 185
Study: 20558806

Group type: EXPERIMENTAL
Intervention: 10-week group intervention plus transdermal nicotine replacement
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group (smokers)
Number of subjects: 360
Study: 17592075

Group type: EXPERIMENTAL
Intervention: Nitinol stent implantation (Bard Luminexx 3 stent)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 244
Study: 16244488

Group type: EXPERIMENTAL
Intervention: One dose of 3 million IU of recombinant interleukin‐2 (rIL‐2) left intracyst after transvaginal ultrasound-guided drainage
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Two doses of 3 million IU of recombinant interleukin‐2 (rIL‐2) left intracyst after transvaginal ultrasound-guided drainage
Number of subjects: 24
Study: 11862375

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 92
Study: 10211174

Group type: EXPERIMENTAL
Intervention: Bupropion sustained-release at 100, 150, or 300 mg/day for six weeks after target quit date (TQD)
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Bupropion sustained-release
Number of subjects: 615

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615
Study: 8570432

Group type: EXPERIMENTAL
Intervention: 5-FU with leucovorin (LV)
Number of subjects: 210

Group type: COMPARATOR
Intervention: 5-FU alone
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 210
Study: 2239164

Group type: EXPERIMENTAL
Intervention: Rydell four-flanged nail
Number of subjects: 200

Group type: COMPARATOR
Intervention: Gouffon pins
Number of subjects: 200
Study: 176034

Group type: COMPARATOR
Intervention: Angiotensin II infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dexamethasone infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethacrynic acid administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethacrynic acid administration with both renin and ACTH suppression
Number of subjects: 0
Study: 28786908

Group type: EXPERIMENTAL
Intervention: Frailty group
Number of subjects: 26
Study: 27428680

Group type: EXPERIMENTAL
Intervention: Kinesiology taping applied in the first and second weeks postsurgery, each application lasting 5 days.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standardized postoperative physiotherapy (Control group).
Number of subjects: 60
Study: 25887581

Group type: EXPERIMENTAL
Intervention: Roland Morris Disability Questionnaire (RMDQ)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Transition questions
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: In-depth interviews
Number of subjects: 35
Study: 23714270

Group type: EXPERIMENTAL
Intervention: Economic support (monthly voucher of ZAR120.00)
Number of subjects: 4091

Group type: COMPARATOR
Intervention: Usual tuberculosis care
Number of subjects: 4091
Study: 16782096

Group type: EXPERIMENTAL
Intervention: HPV-positive women
Number of subjects: 106
Study: 15617929

Group type: EXPERIMENTAL
Intervention: Handheld keratometry in upright position
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Handheld keratometry with rotation (5, 10, 15 degrees anticlockwise and clockwise)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Topographic keratometry
Number of subjects: 33
Study: 10859436

Group type: EXPERIMENTAL
Intervention: Alpha-adrenergic receptor antagonists (alpha-blockers) including prazosin, alfuzosin, indoramin, terazosin, doxazosin, and tamsulosin.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finasteride.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamsulosin (alpha(1a)-receptor-selective blocker).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other less selective alpha-blockers.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finasteride and tamsulosin.
Number of subjects: 0
Study: 8834935

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Zolpidem 15 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 1557677

Group type: EXPERIMENTAL
Intervention: Ten weekly sessions of counselling for parents of patients
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard after-care of medication and support
Number of subjects: 36
Study: 3912040

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCL; Paspertin)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Alizapride (AZP; Vergentan)
Number of subjects: 19
Study: 31229206

Group type: EXPERIMENTAL
Intervention: Home-hospitalization
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard ambulatory hospital care
Number of subjects: 30
Study: 28540870

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg OD
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo OD
Number of subjects: 28
Study: 26189154

Group type: EXPERIMENTAL
Intervention: Combination intervention strategy (CIS) including point‐of‐care CD4 testing, accelerated ART initiation, mobile phone appointment reminders, care and prevention packages, non‐cash financial incentives for linkage and retention.
Number of subjects: 2200

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: Combination intervention strategy (CIS)
Number of subjects: 2200
Study: 23321216

Group type: EXPERIMENTAL
Intervention: Self-administered OGTT at home (unaided)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Self-administered OGTT in clinic (unaided but observed)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Self-administered OGTT performed by a nurse with laboratory glucose assays
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Device glucose measurements
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Repeat testing across settings
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall OGTTs performed
Number of subjects: 30
Study: 22009649

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (Group A)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo treatment (Group B)
Number of subjects: 87
Study: 19401478

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 0
Study: 17476008

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (250 kU)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no additional therapy)
Number of subjects: 41
Study: 15564354

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention (PSI) involving up to 16 sessions conducted in the home by a mental health worker.
Number of subjects: 291

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 291
Study: 11480804

Group type: COMPARATOR
Intervention: Nonabused children
Number of subjects: 70

Group type: COMPARATOR
Intervention: Younger boys (abused)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Abused children (more severe sexual abuse)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Abused and nonabused children
Number of subjects: 70
Study: 9543129

Group type: EXPERIMENTAL
Intervention: Oral etidronate 400 mg/day for 14 days, followed by 76 days of oral calcium carbonate (500 mg elemental calcium), cycled over 12 months.
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo for 14 days, followed by 76 days of oral calcium carbonate (500 mg elemental calcium), cycled over 12 months.
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Etidronate group
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 117
Study: 10155484

Group type: EXPERIMENTAL
Intervention: Bag-Valve (BV)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Demand-Valve (DV)
Number of subjects: 39
Study: 2724504

Group type: EXPERIMENTAL
Intervention: Epidural morphine sulfate (6 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 24
Study: 31058640

Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Black coffee
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Green tea
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Distilled water
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Composite resins
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Test solutions
Number of subjects: 160
Study: 28582810

Group type: EXPERIMENTAL
Intervention: Lactobacillus supplementation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25111465

Group type: EXPERIMENTAL
Intervention: Social Skills Improvement System Classwide Intervention Program (SSIS-CIP)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 432
Study: 24195206

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with Wenxin granule (9 g, 3 times a day for 4 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wenxin granule alone (9 g, 3 times a day for 4 weeks)
Number of subjects: 60
Study: 22145388

Group type: EXPERIMENTAL
Intervention: Ingavirin (90 mg once a day)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Oseltamivir (150 mg twice a day)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Ingavirin
Number of subjects: 194

Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Ingavirin and Oseltamivir
Number of subjects: 194
Study: 19332186

Group type: EXPERIMENTAL
Intervention: Free generic samples of hydrochlorothiazide for hypertensive patients
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Free generic samples of simvastatin for patients with hyperlipidemia
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Free generic samples (combined intervention)
Number of subjects: 660

Group type: COMPARATOR
Intervention: No samples (control group)
Number of subjects: 660
Study: 16357613

Group type: COMPARATOR
Intervention: Infliximab (5 mg/kg) alone
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) with methotrexate (20 mg/week)
Number of subjects: 19
Study: 15612659

Group type: EXPERIMENTAL
Intervention: Probiotic capsules containing Bifidobacterium, Lactobacillus acidophilus and Enterococcus for 14 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Probiotic capsules containing Bacillus subtilis and Enterococcus faecium for 14 days
Number of subjects: 50
Study: 11096238

Group type: EXPERIMENTAL
Intervention: High-energy TUMT (Prostasoft 2.5)
Number of subjects: 147

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 147
Study: 9279061

Group type: EXPERIMENTAL
Intervention: Iron-folate supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8354721

Group type: EXPERIMENTAL
Intervention: Manual toothbrush (M)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Blend-a-Dent electric toothbrush (BL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Braun Plak Control (BPC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Interplak (IP)
Number of subjects: 20
Study: 3789471

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (salbutamol)
Number of subjects: 41
Study: 31172821

Group type: EXPERIMENTAL
Intervention: Human stem cell-conditioned media (HSCM) applied after fractional CO2 laser
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal saline applied after fractional CO2 laser (Control)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hyaluronic acid (HA) applied after fractional CO2 laser (Control)
Number of subjects: 15
Study: 29996243

Group type: EXPERIMENTAL
Intervention: Social support status assessment using social support revalued scale and general questionnaire.
Number of subjects: 0
Study: 27459523

Group type: EXPERIMENTAL
Intervention: AZD4901 80 mg/day
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 24899360

Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (200 mg capsules containing 65 mg of iron), taken at mealtimes twice daily for one week.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo, taken at mealtimes twice daily for one week.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (200 mg capsules containing 65 mg of iron), during the wash-out week.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo, during the wash-out week.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ferrous sulphate vs. placebo for specific symptoms (heartburn, abdominal pain, black stools).
Number of subjects: 20
Study: 23176731

Group type: EXPERIMENTAL
Intervention: High flux HD with exercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: Post-dilution HDF
Number of subjects: 15

Group type: COMPARATOR
Intervention: High flux HD
Number of subjects: 15
Study: 20304503

Group type: EXPERIMENTAL
Intervention: Venlafaxine Extended Release (ER) for Two Years
Number of subjects: 1047
Study: 19029275

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (50 mg/kg for 4 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monthly intravenous cyclophosphamide (750 mg/m²)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both cyclophosphamide regimens
Number of subjects: 0
Study: 16102627

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic sympathectomy (VTS) at T2 ganglion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic sympathectomy (VTS) at T3 ganglion
Number of subjects: 60
Study: 12412870

Group type: COMPARATOR
Intervention: Standard preterm formula without long-chain polyunsaturated fatty acids
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Formula supplemented with docosahexaenoic acid (0.015 g/100 ml) and arachidonic acid (0.031 g/100 ml)
Number of subjects: 42
Study: 10873425

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8884648

Group type: EXPERIMENTAL
Intervention: Sonic toothbrush
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 40
Study: 1857534

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO3)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Aluminium hydroxide (Al(OH)3)
Number of subjects: 11
Study: 6218927

Group type: EXPERIMENTAL
Intervention: Mefloquine 20 mg/kg in children
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Mefloquine 30 mg/kg in children
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Mefloquine 750 mg in adults
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Mefloquine 1000 mg in adults
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Mefloquine (any dose)
Number of subjects: 149
Study: 31859138

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 2275

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 2275
Study: 31438906

Group type: EXPERIMENTAL
Intervention: Nurse‐Family Partnership, a home visitation program
Number of subjects: 739
Study: 26076757

Group type: EXPERIMENTAL
Intervention: Laggera pterodonta mixture
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control mixture
Number of subjects: 133
Study: 26112176

Group type: EXPERIMENTAL
Intervention: 500 ppm F plus 1% TMP
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1,100 ppm F
Number of subjects: 10

Group type: COMPARATOR
Intervention: 500 ppm F
Number of subjects: 10
Study: 23731922

Group type: EXPERIMENTAL
Intervention: Intracoronary nicorandil (4 mg)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no nicorandil)
Number of subjects: 81
Study: 21570554

Group type: EXPERIMENTAL
Intervention: Condoms
Number of subjects: 4905

Group type: EXPERIMENTAL
Intervention: Injectables
Number of subjects: 4905

Group type: EXPERIMENTAL
Intervention: Oral Contraceptives (OC)
Number of subjects: 4905

Group type: COMPARATOR
Intervention: Condoms plus diaphragm
Number of subjects: 4905
Study: 19235749

Group type: EXPERIMENTAL
Intervention: Computer-assisted learning (CAL)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Text-based learning
Number of subjects: 47
Study: 16810141

Group type: EXPERIMENTAL
Intervention: Allon Thermowrap system
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional temperature management method
Number of subjects: 100
Study: 12394847

Group type: EXPERIMENTAL
Intervention: Gengraf
Number of subjects: 50

Group type: COMPARATOR
Intervention: Neoral
Number of subjects: 50
Study: 10550135

Group type: EXPERIMENTAL
Intervention: Paclitaxel (250 mg/m²) as 24-hour infusion
Number of subjects: 174

Group type: COMPARATOR
Intervention: FAC (fluorouracil, doxorubicin, and cyclophosphamide in standard doses at every-3-week intervals)
Number of subjects: 174
Study: 7845867

Group type: EXPERIMENTAL
Intervention: Chemo-endocrine therapy (orchiectomy and/or diethylstilbestrol diphosphate (DES-DP) plus Cisplatin, with or without other cytotoxic agents)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Endocrine therapy alone
Number of subjects: 129
Study: 2104073

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate 120 mg q.d.s.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Colloidal bismuth subcitrate 240 mg b.d.
Number of subjects: 60
Study: 350052

Group type: EXPERIMENTAL
Intervention: mepivacaine 2% with hyaluronidase
Number of subjects: 27

Group type: COMPARATOR
Intervention: mepivacaine 2% alone
Number of subjects: 27
Study: 7043713

Group type: EXPERIMENTAL
Intervention: Fluproquazone
Number of subjects: 170

Group type: COMPARATOR
Intervention: Dextropropoxyphene hydrochloride-paracetamol (Cosalgesic)
Number of subjects: 170
Study: 31254481

Group type: EXPERIMENTAL
Intervention: icosapent ethyl (a purified and stabilized ethyl ester of EPA)
Number of subjects: 0
Study: 29224040

Group type: EXPERIMENTAL
Intervention: cTBS (continuous theta burst stimulation)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 86
Study: 26866296

Group type: EXPERIMENTAL
Intervention: Simulation-based deliberate practice
Number of subjects: 28

Group type: COMPARATOR
Intervention: Self-guided practice
Number of subjects: 28
Study: 24180699

Group type: EXPERIMENTAL
Intervention: Tramadol 5 mg/kg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Tramadol 10 mg/kg
Number of subjects: 9
Study: 22946957

Group type: EXPERIMENTAL
Intervention: Individualised psycho-education focusing on behaviours prior to and during illness-related crisis, distribution of a crisis card, and 24-month preventive monitoring of individual risk factors for compulsory re-admission.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care procedures (control group).
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Individualised psycho-education and monitoring.
Number of subjects: 200
Study: 19933175

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 50 mg kg(‐1) for 15 min and then 15 mg kg(‐1) h(‐1) by continuous i.v. infusion until the end of surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isotonic saline over the same period
Number of subjects: 40
Study: 17565435

Group type: EXPERIMENTAL
Intervention: 3 mg melatonin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2.5 mg dronabinol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 16245488

Group type: EXPERIMENTAL
Intervention: Study stimulus consisting of 1 to 4 curved contours presented briefly followed by a single contour stimulus after a retention interval.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study stimuli always consisted of 4 items, with varying numbers of memorised items in each condition.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study stimuli with set size 4 compared to set size 1.
Number of subjects: 0
Study: 11818760

Group type: EXPERIMENTAL
Intervention: P6 Acupuncture
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 120
Study: 10450298

Group type: EXPERIMENTAL
Intervention: DASH dietary intervention
Number of subjects: 0
Study: 7484482

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (OTB)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2187615

Group type: EXPERIMENTAL
Intervention: Antimicrobial-containing varnish (with chlorhexidine and thymol)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control varnish (no active ingredients)
Number of subjects: 10
Study: 7393998

Group type: EXPERIMENTAL
Intervention: High-dose Fluphenazine-Decanoate (average dose 225 mg in 14 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard-dose Fluphenazine-Decanoate (25 mg in 14 days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-dose Fluphenazine-Decanoate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard-dose Fluphenazine-Decanoate
Number of subjects: 40